CONGRESS PRESENTATIONS
CROI 2024
Denver, Colorado
March 3-6, 2024
2024 Post CROI Conference
Scientific Engagement Webinar - with panel discussion and audience Q&A
Cabotegravir Prevention
Liu A, et. al.
Liu A, et. al.
- Full Poster
- Title
- Introduction
- Methods
- Results
- To deliver CAB LA for PrEP, healthcare staff in the United States used telehealth services from online appointment scheduling to at-home testing and injections and found such services acceptable, feasible, easy, and helpful to use
- Acceptability and Feasibility
- Use of Telehealth Systems Across the Entire Telehealth Journey for CAB LA Delivery by DI SSPs at M4
- Utility of Implementation Resources for CAB LA Delivery
- Conclusions
- Disclaimer
Cabotegravir Treatment
Latham C, et. al.
Latham C, et. al.
- Full Poster
- Title
- Introduction
- Methods
- In the SOLAR study, HIV-1 viral blips were not associated with confirmed virologic failure, consistent with prior Phase 3 clinical study data
- Results
- Participants With HIV-1 Blips and/or CVF
- Snapshot Outcomes for Participants Without Blips (mITT-E)
- Snapshot Outcomes for Participants With Blips (mITT-E)
- Proportion of Participants With Blips by Visit (mITT-E)
- Proportions of Participants With HIV-1 RNA <40 Copies/mL and TND by Visit (mITT-E)
- Conclusions
- Disclaimer
Han K, et. al.
Han K, et. al.
- Full Poster
- Title
- Introduction
- Methods
- PPK Model
- Simulation
- CAB Plasma Concentration Benchmark
- Population PK simulations demonstrate the potential for chronic thigh injections QM and intermittent thigh injections both QM and Q2M of up to 2 consecutive thigh injections but not for chronic Q2M thigh injections
- PPK Model
- Results
- Intraindividual Correlation of Post Hoc Estimates of KAthigh and KAgluteal
- Random Effects (ETA) of Thigh PK Parameters vs. Covariates
- Parameter Estimates of the Final Model
- pcVPC of the Final Model for Predicting PK Data Following Thigh Injections
- Simulated Chronic CAB QM (A) and Q2M (B) Administration to the Lateral Thigh and Gluteal Muscles
- Simulated Intermittent CAB Q2M Administration to the Lateral Thigh and Gluteal Muscles
- Conclusions
- Disclaimer
Dolutegravir-based Regimens
Sörstedt E, et al.
Sörstedt E, et al.
- Full Poster
- Title
- Introduction
- Methods
- A Flowchart Summarizing the Population Analyzed in This Study
- Switching to DTG+3TC is an effective strategy for maintaining virologic suppression in routine clinical practice
- Baseline Characteristics
- Sample Sizes (n) at Each Time-Point in Intent-to-Treat and On-Treatment Analysis Sets
- Results
- Absolute Virologic Failure Counts Occurring in Different Time-Points in the Intent-to-Treat Analysis Set
- Absolute Virologic Failure Counts Occurring in Different Time-Points in the On-Treatment Analysis Set
- Adjusted Virologic Failure Rates (per 10000 PLHIV, 95% CI) Occurring in Different Time-Points in the On-Treatment Analysis Set
- Limitations
- Conclusions
- Disclaimer
Pipeline
Ferris R, et. al.
Ferris R, et. al.
Jeffrey J, et. al.
Jeffrey J, et. al.
McAuliffe B, et. al.
Win B, et. al.
Win B, et. al.
Han K, et. al.
Han K, et. al.
- Title
- Introduction
- Study Design
- Participant Demographics and Characteristics
- Part A: Pharmacokinetics of CAB200 + rHuPH20
- Part A: Safety of CAB200 + rHuPH20
- New Ultra-Long-Acting Formulation CAB-ULA
- Part C: PK of New Ultra-Long-Acting Formulation CAB-ULA
- Part C: Safety of CAB-ULA
- Pharmacokinetic Simulations of CAB-ULA Q4M Dosing
- Conclusions
- Acknowledgments
- Disclaimer
Leone P, et. al.
Leone P, et. al.
- Title
- Introduction
- BANNER Study Design
- Demographics and Baseline Characteristics
- BANNER Part 1: Dose-Dependent Antiviral Activity
- BANNER Part 2: Dose-Dependent Antiviral Activity
- BANNER Part 2: SC Antiviral Activity
- N6LS Antiviral Activity Correlated With Drug Exposure
- Conclusions
- Acknowledgments
- Disclaimer
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Visit Our HIV Medicines
Find Medical Information organized by product. Explore now
Connect With Our Medical Experts
Find My ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1‑888‑226‑8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch